Vorasidenib
My tumor has IDH1 R132C. That is why IDH inhibition matters here. Vorasidenib is FDA-approved for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation after surgery, and it is the IDH inhibitor I am on now.
My cancer, explained visually
The biology of my cancer, and the treatment strategy I explored with clinicians.
This is how I currently understand the biology of my tumor, what looks promising, what is still uncertain, and how the vaccine idea fits into the larger treatment story.
How I think about treatment
IDH-mutant astrocytoma: targeted IDH inhibition plus exploratory personalized neoantigen vaccination
What I am trying to do is go after the tumor in two different ways: use an FDA-approved IDH inhibitor for the mutation that defines my cancer, and explore a personalized vaccine that tries to make selected tumor mutations visible to my immune system. This is my treatment story, not proof that the vaccine, or the combination, improves outcomes.
Personal neoantigen vaccine
The vaccine is exploratory and personal to my tumor. The combination with IDH inhibition is exploratory too. It uses mutation-spanning peptides, with the goal of helping T cells notice pieces of the cancer that should not exist in normal tissue.
IDH1 R132C tumor biology
IDH pathway inhibition with vorasidenib
Personal neoantigen vaccine
Why it feels novel: I am not thinking of this as a simple sequence of treatments. The idea is
to inhibit mutant IDH activity and reduce 2-HG, while also trying to help the immune system recognize
selected tumor-specific peptide targets. That second part, and the combined strategy, are still
exploratory.
Data portal
Start with the data, then go deeper
I want this page to work less like a polished conclusion and more like a map of the case: what was measured, what I generated, what is public here, and what still needs source reports or direct access.
Timeline
The clinical story
Diagnosis, surgery, surveillance, treatment starts, vaccine milestones, and the life around all of it.
OverviewThe numbers I track
Diagnosis, IDH inhibitor context, somatic calls, peptide funnel counts, TMB/MSI, purity, and PGx coverage.
Vaccine funnelFrom mutations to peptides
How my tumor mutations became a computational peptide list, then a smaller vaccine-design shortlist.
Variant atlasMy tumor findings
IDH1, ATRX, TP53 / Li-Fraumeni context, MGMT methylation, HLA type, and vaccine-relevant peptides.
Raw accessAsk for source data
Raw genome, tumor VCF, peptide-level files, and source reports need privacy boundaries and version notes.
Data
My data
These are the numbers I keep coming back to. Some come directly from my medical reports. Some are first-pass counts from the tools I built to understand the case.
What the tumor isAstrocytoma, IDH-mutant, CNS WHO grade 2right frontal lobe
Why vorasidenib mattersVorasidenibFDA-approved IDH inhibitor for grade 2 IDH-mutant glioma after surgery
Somatic calls649618 genes with somatic evidence
Canonical drivers425 other genes flagged for review
Peptides screened314,801a big first-pass computational list, not clinical candidates
Predicted strong HLA binders2,104peptides predicted to bind strongly
Vaccine-design shortlist18prioritized long-peptide design candidates
TMB / MSI1.5 mut/Mb / MSSearlier TMB estimates varied by assay/reporting method
Tumor purity32%purity estimate used by the run
PGx core-site call rate80%how much of the PGx core set was covered
Personal neoantigen vaccine
How my personalized vaccine candidates were picked
I worked with a pipeline that starts with mutations in my tumor and narrows them down to peptides most likely to be visible to my immune system. Those peptides then become the starting point for a personalized vaccine.
Find mutations that are present in the cancer and different from normal tissue.
Look for mutation-spanning peptides that could be shown by my HLA molecules.
Use selected peptides as patient-specific vaccine material.
The goal is for immune cells to recognize selected pieces of the tumor.
Start with my tumor
Start with tumor sequencing and look for mutation-spanning peptides that should look different from normal self.
Personalized vaccine
CeGAT's vaccine is personalized rather than off-the-shelf: the input is my tumor's molecular profile.
T-cell recognition goal
The point is to help T cells recognize a patient-specific tumor profile, using peptides selected from the tumor's own mutations.
Variant explorer
Here is my tumor data
These are the core tumor findings and vaccine-relevant signals I am sharing from my Tempus, BostonGene, pathology, and report data.
Donate
Support brain cancer research
If this story makes you want to help, these are established places to support brain tumor research, patient programs, and translational work.
National nonprofit
American Brain Tumor Association
Research funding, patient education, and support for people facing brain tumors.
National advocacyNational Brain Tumor Society
Research, policy work, and patient-centered advocacy across brain tumor types.
Academic centerUCSF Brain Tumor Center
Clinical and translational brain tumor research at UCSF.
Translational researchIvy Brain Tumor Center
Early-phase research and trials focused on brain tumor treatment.
Research nonprofitGlioblastoma Foundation
Research support focused on glioblastoma and aggressive brain tumors.
Research foundationSontag Foundation
Funding and programs for brain cancer research and early-career investigators.